KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2025)

Historic Gross Margin for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to 92.23%.

  • Acadia Pharmaceuticals' Gross Margin fell 2400.0% to 92.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.92%, marking a year-over-year increase of 3100.0%. This contributed to the annual value of 91.46% for FY2024, which is 28100.0% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Gross Margin of 92.23% as of Q3 2025, which was down 2400.0% from 92.16% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Gross Margin peaked at 98.59% during Q1 2023, and registered a low of 88.85% during Q1 2024.
  • For the 5-year period, Acadia Pharmaceuticals' Gross Margin averaged around 94.61%, with its median value being 93.09% (2023).
  • Per our database at Business Quant, Acadia Pharmaceuticals' Gross Margin surged by 64500bps in 2022 and then tumbled by -97400bps in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Gross Margin (Quarter) stood at 91.78% in 2021, then grew by 7bps to 98.23% in 2022, then fell by -6bps to 92.26% in 2023, then decreased by -1bps to 91.6% in 2024, then grew by 1bps to 92.23% in 2025.
  • Its Gross Margin was 92.23% in Q3 2025, compared to 92.16% in Q2 2025 and 91.65% in Q1 2025.